Étienne Chatelut

9.0k total citations
234 papers, 6.6k citations indexed

About

Étienne Chatelut is a scholar working on Oncology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Étienne Chatelut has authored 234 papers receiving a total of 6.6k indexed citations (citations by other indexed papers that have themselves been cited), including 109 papers in Oncology, 69 papers in Molecular Biology and 57 papers in Pathology and Forensic Medicine. Recurrent topics in Étienne Chatelut's work include Cancer Treatment and Pharmacology (44 papers), Chemotherapy-induced organ toxicity mitigation (42 papers) and Cancer therapeutics and mechanisms (41 papers). Étienne Chatelut is often cited by papers focused on Cancer Treatment and Pharmacology (44 papers), Chemotherapy-induced organ toxicity mitigation (42 papers) and Cancer therapeutics and mechanisms (41 papers). Étienne Chatelut collaborates with scholars based in France, United States and United Kingdom. Étienne Chatelut's co-authors include Pierre Canal, R. Bugat, Gareth J. Veal, Fabienne Thomas, Angélo Paci, Dominique Levêque, Jos H. Beijnen, Florent Puisset, Nicolas Widmer and Christophe Bardin and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Scientific Reports.

In The Last Decade

Étienne Chatelut

227 papers receiving 6.4k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Étienne Chatelut 2.6k 1.8k 1.0k 783 755 234 6.6k
Jerry M. Collins 3.1k 1.2× 2.7k 1.5× 1.3k 1.2× 579 0.7× 634 0.8× 176 9.0k
François Goldwasser 4.7k 1.8× 2.8k 1.6× 2.1k 2.0× 689 0.9× 484 0.6× 289 8.9k
Hironobu Minami 4.5k 1.7× 2.7k 1.5× 1.7k 1.7× 676 0.9× 472 0.6× 366 9.2k
Nanno H. Mulder 3.4k 1.3× 2.2k 1.3× 935 0.9× 697 0.9× 514 0.7× 229 6.9k
Kenneth R. Hande 3.0k 1.1× 2.6k 1.5× 1.7k 1.6× 816 1.0× 462 0.6× 128 6.8k
Alan V. Boddy 2.2k 0.8× 2.4k 1.4× 670 0.6× 840 1.1× 645 0.9× 188 5.9k
W.W. ten Bokkel Huinink 3.8k 1.4× 2.1k 1.2× 750 0.7× 540 0.7× 536 0.7× 160 6.9k
Walter J. Loos 3.3k 1.2× 2.3k 1.3× 621 0.6× 336 0.4× 529 0.7× 135 5.6k
Peter Nygren 2.7k 1.0× 2.8k 1.6× 768 0.7× 493 0.6× 229 0.3× 234 7.0k
Sharon Marsh 3.0k 1.1× 2.9k 1.7× 648 0.6× 587 0.7× 589 0.8× 109 6.7k

Countries citing papers authored by Étienne Chatelut

Since Specialization
Citations

This map shows the geographic impact of Étienne Chatelut's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Étienne Chatelut with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Étienne Chatelut more than expected).

Fields of papers citing papers by Étienne Chatelut

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Étienne Chatelut. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Étienne Chatelut. The network helps show where Étienne Chatelut may publish in the future.

Co-authorship network of co-authors of Étienne Chatelut

This figure shows the co-authorship network connecting the top 25 collaborators of Étienne Chatelut. A scholar is included among the top collaborators of Étienne Chatelut based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Étienne Chatelut. Étienne Chatelut is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Woillard, Jean‐Baptiste, Sébastien Benzekry, Julie Josse, et al.. (2025). Digital pharmacological twins: Bridging multi-scale modelling and artificial intelligence for precision medicine: The DIGPHAT consortium. Therapies. 81(2). 147–158.
2.
Launay, Manon, Laure Raymond, Jérôme Guitton, et al.. (2024). Can we identify patients carrying targeted deleterious DPYD variants with plasma uracil and dihydrouracil? A GPCO-RNPGx retrospective analysis. Clinical Chemistry and Laboratory Medicine (CCLM). 62(12). 2415–2424.
3.
Chatelut, Étienne, et al.. (2024). Impact of hemolysis on uracilemia in the context of dihydropyrimidine dehydrogenase deficiency testing. Clinical Chemistry and Laboratory Medicine (CCLM). 62(6). e129–e131. 1 indexed citations
4.
Puisset, Florent, Loı̈c Mourey, Damien Pouessel, et al.. (2023). Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cancer. Cancers. 15(1). 313–313. 5 indexed citations
5.
6.
Lambert, Marie, et al.. (2023). Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer. Cancer Chemotherapy and Pharmacology. 91(3). 247–256. 2 indexed citations
7.
Arellano, Cécile, Christelle Vachoux, Christine Chevreau, et al.. (2022). Biological Role of Pazopanib and Sunitinib Aldehyde Derivatives in Drug-Induced Liver Injury. Metabolites. 12(9). 852–852. 3 indexed citations
8.
Puisset, Florent, et al.. (2021). Easy and reliable maximum a posteriori Bayesian estimation of pharmacokinetic parameters with the open‐source R package mapbayr. CPT Pharmacometrics & Systems Pharmacology. 10(10). 1208–1220. 24 indexed citations
9.
Thomas, Fabienne, Mélanie White‐Koning, Ben Allal, et al.. (2021). Limited Sampling Strategy for Determination of Ibrutinib Plasma Exposure: Joint Analyses with Metabolite Data. Pharmaceuticals. 14(2). 162–162. 4 indexed citations
10.
Chevreau, Christine, Caroline Delmas, Jean‐Yves Blay, et al.. (2020). Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma. Cancers. 12(12). 3647–3647. 3 indexed citations
11.
Alix‐Panabières, Catherine, Thierry Lafont, Ben Allal, et al.. (2019). Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients. British Journal of Clinical Pharmacology. 85(6). 1357–1366. 19 indexed citations
12.
Thomas, Fabienne, Gareth J. Veal, Souleiman El Balkhi, et al.. (2018). Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case report. Cancer Chemotherapy and Pharmacology. 82(2). 361–365. 7 indexed citations
13.
Chatelut, Étienne, et al.. (2018). Efavirenz and Lopinavir Levels in HIV-Infected Women and Their Nursing Infants, in Mali. Journal of Pharmacology and Experimental Therapeutics. 366(3). 479–484. 4 indexed citations
14.
Chevreau, Christine, Sophie Broutin, Jérôme Guitton, et al.. (2017). Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study. Clinical Cancer Research. 23(23). 7171–7179. 14 indexed citations
15.
Massabeau, Carole, Jonathan Khalifa, Thomas Filleron, et al.. (2017). Continuous Infusion of Cilengitide Plus Chemoradiotherapy for Patients With Stage III Non–Small-cell Lung Cancer: A Phase I Study. Clinical Lung Cancer. 19(3). e277–e285. 21 indexed citations
16.
Thomas, Fabienne, Étienne Chatelut, Sarah Bétrian, et al.. (2013). Irreversible Hepatotoxicity After Administration of Trabectedin to a Pleiomorphic Sarcoma Patient with a Rare ABCC2 Polymorphism: A Case Report. Pharmacogenomics. 14(12). 1389–1396. 7 indexed citations
17.
Freyer, Gilles, G. Milano, Étienne Chatelut, et al.. (2011). Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study.. PubMed. 31(1). 359–66. 14 indexed citations
18.
Pétain, Aurélie & Étienne Chatelut. (2008). [Anticancer drug dose individualisation: from body surface area to physiology].. PubMed. 95(10). 895–901. 4 indexed citations
19.
Séronie-Vivien, Sophie, et al.. (2000). Comparaison de la méthode de Jaffé modifiée et d’une méthode enzymatique de dosage de la créatinine sérique : conséquences pratiques d’un changement de méthode au sein d’un laboratoire de biologie clinique oncologique. Annales de biologie clinique. 58(4). 499–504. 4 indexed citations
20.
Martin, Laure, et al.. (1998). Amélioration de l’équation de Cockcroft-Gault pour prédire le débit de filtration glomérulaire chez les patients cancéreux. Bulletin du Cancer. 85(7). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jerry M. Collins Breakdown of academic impact, for papers by François Goldwasser Breakdown of academic impact, for papers by Hironobu Minami Breakdown of academic impact, for papers by Nanno H. Mulder Breakdown of academic impact, for papers by Kenneth R. Hande Breakdown of academic impact, for papers by Alan V. Boddy Breakdown of academic impact, for papers by W.W. ten Bokkel Huinink Breakdown of academic impact, for papers by Walter J. Loos Breakdown of academic impact, for papers by Peter Nygren Breakdown of academic impact, for papers by Sharon Marsh
Rankless by CCL
2026